VRDN
Viridian Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | -12 | 71.65M | $1.32B | +6 | −18 |
| Q1 2026 | 88 | +7 | 66.96M | $1.32B | +11 | −5 |
| Q4 2025 | 82 | +2 | 62.58M | $1.95B | +4 | −1 |
| Q3 2025 | 16 | -1 | 34.97M | $754.70M | — | −1 |
| Q2 2025 | 14 | -2 | 33.44M | $467.46M | — | −2 |
| Q1 2025 | 13 | +2 | 10.47M | $141.20M | +2 | — |
| Q4 2024 | 11 | -2 | 10.88M | $208.63M | — | −2 |
| Q3 2024 | 12 | +3 | 5.78M | $131.57M | +3 | — |
| Q2 2024 | 9 | — | 3.15M | $40.97M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.49M | +5.8% | $33.98M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.49M | +5.8% | $33.98M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Adage Capital Partners ✦ | 1.21M | New | $27.41M | 0.0% | New | 1 | SEC ↗ |
| 4 | Marshall Wace ✦ | 684.80K | +838.4% | $15.58M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Marshall Wace ✦ | 684.80K | +838.4% | $15.58M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Millennium Management ✦ | 668.04K | +192.8% | $15.20M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Fisher Asset Management ✦ | 494.92K | +25.1% | $11.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 482.14K | +14.8% | $10.97M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 241.27K | +440.1% | $5.49M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 235.99K | -16.9% | $5.37M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 235.99K | -16.9% | $5.37M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 138.07K | New | $3.14M | 0.0% | New | 1 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 59.60K | -75.9% | $1.36M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 45.01K | +1.3% | $1.02M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 34.63K | New | $787,766 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $27.41M | 0.0% |
| D. E. Shaw & Co. | $3.14M | 0.0% |
| Point72 Asset Management | $787,766 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 225 holders, 111.32M shares, $2.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 4.21K sh · $103,194
Officer · 10.00K sh · $245,000
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology